Phaseline

Companies › CStone Pharmaceuticals

CStone Pharmaceuticals: clinical trials, targets and expected readouts

4 active drug programs in 4 registered trials: 2 Phase 1, 1 Phase 3, 1 Phase 2; Oncology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Cs-1003 (CS1003)
Programmed cell death protein 1 inhibitor
PDCD1Phase 3Hepatocellular Carcinoma–
Lorlatinib
ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor
ALK, EML4Phase 2Advanced or Metastatic ROS1-Positive Non-Small Cell Lung CancerMay 2027
CS2009–Phase 1Advanced Solid TumorsJan 2027
CS5007–Phase 1Advanced Solid TumorsJan 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04194775Cs-1003 (CS1003)Phase 3Hepatocellular CarcinomaOncologyJun 2025
NCT06741644CS2009Phase 1Advanced Solid TumorsOncologyJan 2027
NCT05297890LorlatinibPhase 2Advanced or Metastatic ROS1-Positive Non-Small Cell Lung CancerOncologyMay 2027
NCT07622524CS5007Phase 1Advanced Solid TumorsOncologyJan 2028

Targets

PDCD1 (1) ALK (1) EML4 (1)

Companies with the same targets

Pfizer Akeso Roche Sichuan Baili Pharmaceutical Innovent Biologics (Suzhou) Shanghai Henlius Biotech Novartis AstraZeneca Shenyang Sunshine Pharmaceutical Regeneron Pharmaceuticals

Companies built like this

Shenzhen TargetRx TaiRx Nuvalent CSPC Megalith Biopharmaceutical Stemline Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.